nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2024-3-123-129nnp-2282Research ArticleREVIEWSОБЗОРЫPsychotic disorders in Parkinson's disease: phenomenology, pathogenesis, therapeutic approaches (modern view on the problem)Психотические нарушения при болезни Паркинсона: феноменология, патогенез, подходы к терапии (современный взгляд на проблему)https://orcid.org/0009-0008-9502-7578АлизадеХ. И.AlizadeKh. I.

Ализаде Хадиджа Интигам кызы.

125367, Москва, Волоколамское шоссе, 80

Khadija I. Alizadeh.

80, Volokolamskoe shosse, Moscow 125367

Chadi19966@mail.ruhttps://orcid.org/0000-0002-4370-4249РагимоваА. А.RagimovaA. A.

125367, Москва, Волоколамское шоссе, 80

80, Volokolamskoe shosse, Moscow 125367

https://orcid.org/0000-0001-8070-7644ФедотоваЕ. Ю.FedotovaE. Yu.

125367, Москва, Волоколамское шоссе, 80

80, Volokolamskoe shosse, Moscow 125367

https://orcid.org/0000-0002-2704-6282ИллариошкинС. Н.IllarioshkinS. N.

125367, Москва, Волоколамское шоссе, 80

80, Volokolamskoe shosse, Moscow 125367

ФГБНУ «Научный центр неврологии»РоссияResearch Center of NeurologyRussian Federation202422062024163123129Copyright © Alizade K.I., Ragimova A.A., Fedotova E.Y., Illarioshkin S.N., 20242024Ализаде Х.И., Рагимова А.А., Федотова Е.Ю., Иллариошкин С.Н.Alizade K.I., Ragimova A.A., Fedotova E.Y., Illarioshkin S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/2282

Psychotic disorders in Parkinson's disease (PD) are common non-motor manifestations that have a negative impact on the quality of life of patients and are associated with an unfavourable prognosis. The development and progression of psychotic symptoms in patients with PD is due to a combination of exogenous and endogenous mechanisms, such as an imbalance of neurotransmitter systems, the effect of antiparkinsonian drugs, individual characteristics of the disease course and structural neurodegenerative changes in the brain. Given the heterogeneity of psychotic symptoms and the lack of standardized diagnostic criteria, issues of timely identification and choice of therapeutic tactics are important and require special attention from neurologists and psychiatrists in clinical practise. This review highlights modern ideas on phenomenology, risk factors, pathogenesis and therapeutic approaches.

Психотические нарушения при болезни Паркинсона — распространенные немоторные проявления, оказывающие негативное влияние на качество жизни пациентов и ассоциированные с неблагоприятным прогнозом течения болезни. В основе развития и прогрессирования психотических симптомов у пациентов с болезнью Паркинсона лежит сочетание экзогенных и эндогенных механизмов, таких как дисбаланс нейромедиаторных систем, действие противопаркинсонических препаратов, индивидуальные особенности течения заболевания и структурные нейродегенеративные изменения головного мозга. Учитывая гетерогенность психотических симптомов и отсутствие стандартизированных диагностических критериев, вопросы своевременного выявления и выбора терапевтической тактики являются актуальными и требуют особого внимания неврологов и психиатров в клинической практике. В данном обзоре освещены современные представления о феноменологии, факторах риска, патогенезе и подходах к терапии.

болезнь Паркинсонапсихозпсихотические нарушениязрительные галлюцинациималые галлюцинациибредатипичные нейролептикиParkinson's diseasepsychosispsychotic disordersvisual hallucinationsminor hallucinationsdelusionatypical neurolepticsReferencesЛевин ОС, Аникина МА, Шиндряева НН, Зимнякова ОС. Психотические нарушения при болезни Паркинсона и деменции с тельцами Леви. Журнал неврологии и психиатрии им. С.С. Корсакова. 2011;111(6):82-8.Levin OS, Anikina MA, Shyndryaeva NN, Zymnyakova OS. Psychotic disorders in Parkinson's disease and dementia with Lewy bodies. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(6):82-8 (In Russ.).Таппахов АА, Попова ТЕ, Николаева ТЯ и др. Нейропсихологическая картина болезни Паркинсона. Неврология, нейропсихиатрия, психосоматика. 2017;9(4):82-7. doi: 10.14412/2074-2711-2017-4-82-87Tappakhov AA, Popova TE, Nikolaeva TYa, et al. Neuropsychological pattern of Parkinson's disease. Nevrologiya, neuropsykhiatriya, psykhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(4):82-7. doi: 10.14412/2074-2711-2017-4-82-87 (In Russ.).Нодель МР, Яхно НН. Нервно-психические нарушения при болезни Паркинсона. Неврология, нейропсихиатрия, психосоматика. 2009;1(2):3-8.Nodel MR, Yakhno NN. Nervous and mental disorders of Parkinson's disease. Nevrologiya, neuropsykhiatriya, psykhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2009;1(2):3-8 (In Russ.).Seppi K, Ray Chaudhuri K, Coelho M, et al; the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord. 2019 Feb;34(2):180-98. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Erratum in: Mov Disord. 2019 May;34(5):765.Seppi K, Ray Chaudhuri K, Coelho M, et al; the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord. 2019 Feb;34(2):180-98. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Erratum in: Mov Disord. 2019 May;34(5):765.Weintraub D, Burn DJ. Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord. 2011 May;26(6):1022-31. doi: 10.1002/mds.23664Weintraub D, Burn DJ. Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord. 2011 May;26(6):1022-31. doi: 10.1002/mds.23664Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain. 2000 Apr;123 (Pt 4):733-45. doi: 10.1093/brain/123.4.733Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain. 2000 Apr;123 (Pt 4):733-45. doi: 10.1093/brain/123.4.733Stang CD, Mullan AF, Camerucci E, et al. Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson's Disease (1991—2010). J Parkinsons Dis. 2022;12(4):1319-27. doi: 10.3233/JPD-213035Stang CD, Mullan AF, Camerucci E, et al. Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson's Disease (1991—2010). J Parkinsons Dis. 2022;12(4):1319-27. doi: 10.3233/JPD-213035Chendo I, Fabbri M, Godinho C, et al. High frequency of psychosis in late-stage Parkinson's disease. Clin Park Relat Disord. 2021 Nov 24;5:100119. doi: 10.1016/j.prdoa.2021.100119Chendo I, Fabbri M, Godinho C, et al. High frequency of psychosis in late-stage Parkinson's disease. Clin Park Relat Disord. 2021 Nov 24;5:100119. doi: 10.1016/j.prdoa.2021.100119Pachi I, Papadopoulos V, Koros C, et al. Comprehensive Evaluation of Psychotic Features and Their Clinical Correlates in Early Parkinson's Disease. J Parkinsons Dis. 2023;13(7):1185-97. doi: 10.3233/JPD-230056Pachi I, Papadopoulos V, Koros C, et al. Comprehensive Evaluation of Psychotic Features and Their Clinical Correlates in Early Parkinson's Disease. J Parkinsons Dis. 2023;13(7):1185-97. doi: 10.3233/JPD-230056Weintraub D. Progress Regarding Parkinson's Disease Psychosis: It's No Illusion. Mov Disord Clin Pract. 2016 Aug 11;3(5):431-4. doi: 10.1002/mdc3.12377Weintraub D. Progress Regarding Parkinson's Disease Psychosis: It's No Illusion. Mov Disord Clin Pract. 2016 Aug 11;3(5):431-4. doi: 10.1002/mdc3.12377Yoritaka A, Shimo Y, Takanashi M, et al. Motor and non-motor symptoms of 1453 patients with Parkinson's disease: prevalence and risks. Parkinsonism Relat Disord. 2013 Aug;19(8):725-31. doi: 10.1016/j.parkreld-is.2013.04.001. Epub 2013 Apr 29.Yoritaka A, Shimo Y, Takanashi M, et al. Motor and non-motor symptoms of 1453 patients with Parkinson's disease: prevalence and risks. Parkinsonism Relat Disord. 2013 Aug;19(8):725-31. doi: 10.1016/j.parkreld-is.2013.04.001. Epub 2013 Apr 29.Pagonabarraga J, Martinez-Horta S, Fernandez de Bobadilla R, et al. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. Mov Disord. 2016 Jan;31(1):45-52. doi: 10.1002/mds.26432. Epub 2015 Sep 26. Erratum in: Mov Disord. 2016 Mar;31(3):433.Pagonabarraga J, Martinez-Horta S, Fernandez de Bobadilla R, et al. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. Mov Disord. 2016 Jan;31(1):45-52. doi: 10.1002/mds.26432. Epub 2015 Sep 26. Erratum in: Mov Disord. 2016 Mar;31(3):433.Ffytche DH, Creese B, Politis M, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017 Feb;13(2):81-95. doi: 10.1038/nrneurol.2016.200. Epub 2017 Jan 20.Ffytche DH, Creese B, Politis M, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017 Feb;13(2):81-95. doi: 10.1038/nrneurol.2016.200. Epub 2017 Jan 20.Fenelon G, Soulas T, Cleret de Langavant L, et al. Feeling of presence in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2011 Nov;82(11):1219-24. doi: 10.1136/jnnp.2010.234799. Epub 2011 May 7.Fenelon G, Soulas T, Cleret de Langavant L, et al. Feeling of presence in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2011 Nov;82(11):1219-24. doi: 10.1136/jnnp.2010.234799. Epub 2011 May 7.Nishio Y, Yokoi K, Hirayama K, et al. Defining visual illusions in Parkinson's disease: Kinetopsia and object misidentification illusions. Parkinsonism Relat Disord. 2018 Oct;55:111-6. doi: 10.1016/j.parkreld-is.2018.05.023. Epub 2018 May 28.Nishio Y, Yokoi K, Hirayama K, et al. Defining visual illusions in Parkinson's disease: Kinetopsia and object misidentification illusions. Parkinsonism Relat Disord. 2018 Oct;55:111-6. doi: 10.1016/j.parkreld-is.2018.05.023. Epub 2018 May 28.Аленикова ОА. Зрительные галлюцинации при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(6):106-13. doi: 10.17116/jnevro2021121061106Alenikova OA. Visual hallucinations in Parkinson's disease. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(6):106-13. doi: 10.17116/jnevro2021121061106 (In Russ.).Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):734-8. doi: 10.1136/jnnp.70.6.734Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):734-8. doi: 10.1136/jnnp.70.6.734Lee AH, Weintraub D. Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord. 2012 Jun;27(7):858-63. doi: 10.1002/mds.25003. Epub 2012 Jun 1.Lee AH, Weintraub D. Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord. 2012 Jun;27(7):858-63. doi: 10.1002/mds.25003. Epub 2012 Jun 1.Eversfield CL, Orton LD. Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies: a systematic review and meta-analysis. Psychol Med. 2019 Oct;49(14):2342-53. doi: 10.1017/S0033291718003161. Epub 2018 Nov 26.Eversfield CL, Orton LD. Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies: a systematic review and meta-analysis. Psychol Med. 2019 Oct;49(14):2342-53. doi: 10.1017/S0033291718003161. Epub 2018 Nov 26.Chou KL, Messing S, Oakes D, et al. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol. 2005 Sep-Oct;28(5):215-9. doi: 10.1097/01.wnf.0000180228.77802.32Chou KL, Messing S, Oakes D, et al. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol. 2005 Sep-Oct;28(5):215-9. doi: 10.1097/01.wnf.0000180228.77802.32Ramirez-Bermudez J, Aguilar-Venegas LC, Crail-Melendez D, et al. Cotard syndrome in neurological and psychiatric patients. J Neuropsychiatry Clin Neurosci. 2010 Fall;22(4):409-16. doi: 10.1176/jnp.2010.22.4.409Ramirez-Bermudez J, Aguilar-Venegas LC, Crail-Melendez D, et al. Cotard syndrome in neurological and psychiatric patients. J Neuropsychiatry Clin Neurosci. 2010 Fall;22(4):409-16. doi: 10.1176/jnp.2010.22.4.409Josephs KA. Capgras syndrome and its relationship to neurodegenerative disease. Arch Neurol. 2007 Dec;64(12):1762-6. doi: 10.1001/archneur.64.12.1762Josephs KA. Capgras syndrome and its relationship to neurodegenerative disease. Arch Neurol. 2007 Dec;64(12):1762-6. doi: 10.1001/archneur.64.12.1762Lawson RA, McDonald C, Burn DJ. Defining delirium in idiopathic Parkinson's disease: A systematic review. Parkinsonism Relat Disord. 2019 Jul;64:29-39. doi: 10.1016/j.parkreldis.2018.09.025. Epub 2018 Sep 26.Lawson RA, McDonald C, Burn DJ. Defining delirium in idiopathic Parkinson's disease: A systematic review. Parkinsonism Relat Disord. 2019 Jul;64:29-39. doi: 10.1016/j.parkreldis.2018.09.025. Epub 2018 Sep 26.Spica V, Pekmezovic Т, Svetel M, Kostic VS. Prevalence of non-motor symptoms in youngonset versus late-onset Parkinson's disease. J Neurol. 2013 Jan;260(1):131-7. doi: 10.1007/s00415-012-6600-9. Epub 2012 Jul 22.Spica V, Pekmezovic Т, Svetel M, Kostic VS. Prevalence of non-motor symptoms in youngonset versus late-onset Parkinson's disease. J Neurol. 2013 Jan;260(1):131-7. doi: 10.1007/s00415-012-6600-9. Epub 2012 Jul 22.Forsaa EB, Larsen JP, Wentzel-Larsen Т, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010 Aug;67(8):996-1001. doi: 10.1001/arch-neurol.2010.166Forsaa EB, Larsen JP, Wentzel-Larsen Т, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010 Aug;67(8):996-1001. doi: 10.1001/arch-neurol.2010.166Morgante L, Colosimo C, Antonini A, et al; PRIAMO Study Group. Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):76-82. doi: 10.1136/jnnp-2011-300043. Epub 2011 Aug 11.Morgante L, Colosimo C, Antonini A, et al; PRIAMO Study Group. Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):76-82. doi: 10.1136/jnnp-2011-300043. Epub 2011 Aug 11.Zhu K, van Hilten JJ, Putter H, Marinus J. Risk factors for hallucinations in Parkinson's disease: results from a large prospective cohort study. Mov Disord. 2013 Jun;28(6):755-62. doi: 10.1002/mds.25389. Epub 2013 Mar 20.Zhu K, van Hilten JJ, Putter H, Marinus J. Risk factors for hallucinations in Parkinson's disease: results from a large prospective cohort study. Mov Disord. 2013 Jun;28(6):755-62. doi: 10.1002/mds.25389. Epub 2013 Mar 20.Fryml LD, Williams KR, Pelic CG, et al. The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status. J Psychiatr Pract. 2017 May;23(3):191-9. doi: 10.1097/PRA.0000000000000237Fryml LD, Williams KR, Pelic CG, et al. The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status. J Psychiatr Pract. 2017 May;23(3):191-9. doi: 10.1097/PRA.0000000000000237Munhoz RP, Teive HA, Eleftherohorinou H, et al. Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):883-7. doi: 10.1136/jnnp-2012-304440. Epub 2013 Mar 5.Munhoz RP, Teive HA, Eleftherohorinou H, et al. Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):883-7. doi: 10.1136/jnnp-2012-304440. Epub 2013 Mar 5.Angelopoulou E, Bougea A, Papageorgiou SG, Villa C. Psychosis in Parkinson's Disease: A Lesson from Genetics. Genes (Basel). 2022 Jun 20;13(6):1099. doi: 10.3390/genes13061099Angelopoulou E, Bougea A, Papageorgiou SG, Villa C. Psychosis in Parkinson's Disease: A Lesson from Genetics. Genes (Basel). 2022 Jun 20;13(6):1099. doi: 10.3390/genes13061099Schneider RB, Iourinets J, Richard IH. Parkinson's disease psychosis: presentation, diagnosis and management. Neurodegener Dis Manag. 2017 Dec;7(6):365-76. doi: 10.2217/nmt-2017-0028. Epub 2017 Nov 21.Schneider RB, Iourinets J, Richard IH. Parkinson's disease psychosis: presentation, diagnosis and management. Neurodegener Dis Manag. 2017 Dec;7(6):365-76. doi: 10.2217/nmt-2017-0028. Epub 2017 Nov 21.Stahl SM. Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectr. 2016 Oct;21(5):355-9. doi: 10.1017/S1092852916000602Stahl SM. Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectr. 2016 Oct;21(5):355-9. doi: 10.1017/S1092852916000602Huot P. 5-HT2A receptors and Parkinson's disease psychosis: a pharmacological discussion. Neurodegener Dis Manag. 2018 Dec;8(6):363-5. doi: 10.2217/nmt-2018-0039Huot P. 5-HT2A receptors and Parkinson's disease psychosis: a pharmacological discussion. Neurodegener Dis Manag. 2018 Dec;8(6):363-5. doi: 10.2217/nmt-2018-0039Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999 Mar 11;340(10):757-63. doi: 10.1056/NEJM199903113401003Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999 Mar 11;340(10):757-63. doi: 10.1056/NEJM199903113401003Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology. 2010 Mar;35(4):881-92. doi: 10.1038/npp.2009.176. Epub 2009 Nov 11.Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology. 2010 Mar;35(4):881-92. doi: 10.1038/npp.2009.176. Epub 2009 Nov 11.Janzen J, van't Ent D, Lemstra AW, et al. The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study.J Neurol. 2012 Jan;259(1):147-54. doi: 10.1007/s00415-011-6149-z. Epub 2011 Jun 30.Janzen J, van't Ent D, Lemstra AW, et al. The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study.J Neurol. 2012 Jan;259(1):147-54. doi: 10.1007/s00415-011-6149-z. Epub 2011 Jun 30.Hepp DH, Ruiter AM, Galis Y, et al. Pedunculopontine cholinergic cell loss in hallucinating Parkinson disease patients but not in dementia with Lewy bodies patients. J Neuropathol Exp Neurol. 2013 Dec;72(12):1162-70. doi: 10.1097/NEN.0000000000000014Hepp DH, Ruiter AM, Galis Y, et al. Pedunculopontine cholinergic cell loss in hallucinating Parkinson disease patients but not in dementia with Lewy bodies patients. J Neuropathol Exp Neurol. 2013 Dec;72(12):1162-70. doi: 10.1097/NEN.0000000000000014Ffytche DH, Pereira JB, Ballard C, et al. Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):325-31. doi: 10.1136/jnnp-2016-314832Ffytche DH, Pereira JB, Ballard C, et al. Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):325-31. doi: 10.1136/jnnp-2016-314832Goldman JG, Stebbins GT, Dinh V, et al. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain. 2014 Mar;137(Pt 3):849-59. doi: 10.1093/brain/awt360. Epub 2014 Jan 29.Goldman JG, Stebbins GT, Dinh V, et al. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain. 2014 Mar;137(Pt 3):849-59. doi: 10.1093/brain/awt360. Epub 2014 Jan 29.Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord. 2007 Jun 15;22(8):1061-8. doi: 10.1002/mds.21382Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord. 2007 Jun 15;22(8):1061-8. doi: 10.1002/mds.21382Fernandez HH, Aarsland D, Fenelon G, et al. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord. 2008 Mar 15;23(4):484-500. doi: 10.1002/mds.21875Fernandez HH, Aarsland D, Fenelon G, et al. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord. 2008 Mar 15;23(4):484-500. doi: 10.1002/mds.21875Козак ВВ. Современные подходы к лечению психотических расстройств при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(10):103-9. doi: 10.17116/jnevro2016116101103-109Cozac VV. Modern approaches to treatment of psychosis in Parkinson's disease. Zhurnal nevrologii i psikhiatrii imeni S.S.Korsakova = S.S.Korsakov Journal of Neurology and Psychiatry.2016;116(10):103-9. doi: 10.17116/jnevro2016116101103-109 (In Russ.).Poewe W, Seppi K. Treatment options for depression and psychosis in Parkinson's disease. J Neurol. 2001 Sep;248 Suppl 3:III12-21. doi: 10.1007/pl00007821Poewe W, Seppi K. Treatment options for depression and psychosis in Parkinson's disease. J Neurol. 2001 Sep;248 Suppl 3:III12-21. doi: 10.1007/pl00007821Weintraub D, Mamikonyan E. The Neuropsychiatry of Parkinson Disease: A Perfect Storm. Am J Geriatr Psychiatry. 2019 Sep;27(9):998-1018. doi: 10.1016/j.jagp.2019.03.002. Epub 2019 Mar 9.Weintraub D, Mamikonyan E. The Neuropsychiatry of Parkinson Disease: A Perfect Storm. Am J Geriatr Psychiatry. 2019 Sep;27(9):998-1018. doi: 10.1016/j.jagp.2019.03.002. Epub 2019 Mar 9.Iketani R, Furushima D, Imai S, Yamada H. Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: A systematic review and Bayesian network meta-analysis. Parkinsonism Relat Disord. 2020 Sep;78:82-90. doi: 10.1016/j.parkreldis.2020.07.021. Epub 2020 Jul 24.Iketani R, Furushima D, Imai S, Yamada H. Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: A systematic review and Bayesian network meta-analysis. Parkinsonism Relat Disord. 2020 Sep;78:82-90. doi: 10.1016/j.parkreldis.2020.07.021. Epub 2020 Jul 24.Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002 Sep;17(5):1031-5. doi: 10.1002/mds.10217Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002 Sep;17(5):1031-5. doi: 10.1002/mds.10217Meco G, Alessandri A, Giustini P, Bonifati V. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord. 1997 Jul;12(4):610-2. doi: 10.1002/mds.870120423Meco G, Alessandri A, Giustini P, Bonifati V. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord. 1997 Jul;12(4):610-2. doi: 10.1002/mds.870120423Pintor L, Valldeoriola F, Bailles E, et al. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol. 2012 Mar-Apr;35(2):61-6. doi: 10.1097/WNF.0b013e31824d5115Pintor L, Valldeoriola F, Bailles E, et al. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol. 2012 Mar-Apr;35(2):61-6. doi: 10.1097/WNF.0b013e31824d5115Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord. 2005 Aug;20(8):958-63. doi: 10.1002/mds.20474Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord. 2005 Aug;20(8):958-63. doi: 10.1002/mds.20474Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord. 2007 Feb 15;22(3):313-8. doi: 10.1002/mds.21116Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord. 2007 Feb 15;22(3):313-8. doi: 10.1002/mds.21116Prohorov T, Klein C, Miniovitz A, et al. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol. 2006 Feb;253(2):171-5. doi: 10.1007/s00415-005-0943-4. Epub 2005 Aug 17.Prohorov T, Klein C, Miniovitz A, et al. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol. 2006 Feb;253(2):171-5. doi: 10.1007/s00415-005-0943-4. Epub 2005 Aug 17.Chen JJ, Hua H, Massihi L, et al. Systematic Literature Review of Quetiapine for the Treatment of Psychosis in Patients With Parkinsonism. J Neuropsychiatry Clin Neurosci. 2019 Summer;31(3):188-95. doi: 10.1176/appi.neuropsych.18080180. Epub 2019 Mar 8.Chen JJ, Hua H, Massihi L, et al. Systematic Literature Review of Quetiapine for the Treatment of Psychosis in Patients With Parkinsonism. J Neuropsychiatry Clin Neurosci. 2019 Summer;31(3):188-95. doi: 10.1176/appi.neuropsych.18080180. Epub 2019 Mar 8.Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1.Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1.Ballard CG, Kreitzman DL, Isaacson S, et al; 015 Study Group. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. Parkinsonism Relat Disord. 2020 Aug;77:100-6. doi: 10.1016/j.parkreldis.2020.06.026. Epub 2020 Jun 28.Ballard CG, Kreitzman DL, Isaacson S, et al; 015 Study Group. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. Parkinsonism Relat Disord. 2020 Aug;77:100-6. doi: 10.1016/j.parkreldis.2020.06.026. Epub 2020 Jun 28.Yasue I, Matsunaga S, Kishi T, et al. Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Metaanalysis of Serotonin 2A Receptor Negative Modulators. J Alzheimers Dis. 2016;50(3):733-40. doi: 10.3233/JAD-150818Yasue I, Matsunaga S, Kishi T, et al. Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Metaanalysis of Serotonin 2A Receptor Negative Modulators. J Alzheimers Dis. 2016;50(3):733-40. doi: 10.3233/JAD-150818Heffernan MLR, Herman LW, Brown S, et al. Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia. ACS Med Chem Lett. 2021 Dec 6;13(1):92-8. doi: 10.1021/acsmedchemlett.1c00527. eCollection 2022 Jan 13.Heffernan MLR, Herman LW, Brown S, et al. Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia. ACS Med Chem Lett. 2021 Dec 6;13(1):92-8. doi: 10.1021/acsmedchemlett.1c00527. eCollection 2022 Jan 13.Isaacson SH, Goldstein M, Pahwa R, et al; Parkinson's Psychosis TAAR1 Study Group. Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT1A Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study. Neurol Clin Pract. 2023 Aug;13(4):e200175. doi: 10.1212/CPJ.0000000000200175. Epub 2023 May 25.Isaacson SH, Goldstein M, Pahwa R, et al; Parkinson's Psychosis TAAR1 Study Group. Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT1A Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study. Neurol Clin Pract. 2023 Aug;13(4):e200175. doi: 10.1212/CPJ.0000000000200175. Epub 2023 May 25.

The authors declare that there are no conflicts of interest present.